doi:10.3969/j.issn.1004-583X.2021.05.018

Abstract

CLC Number:

R749.16

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2021.05.018

https://huicui.hebmu.edu.cn/EN/Y2021/V36/I5/476

References 57

[1]	Ma C, Su L, Xie J, et al. The prevalence and incidence of Parkinson’s disease in China: A systematic review and meta-analysis[J]. J Neural Transm (Vienna), 2014, 121(2):123-134.
[2]	Adler CH, Beach TG, Hentz JG, et al. Low clinical diagnostic accuracy of early vs advanced Parkinson disease: Clinicopathologic study[J]. Neurology, 2014, 83(5):406-412. doi: 10.1212/WNL.0000000000000641 URL
[3]	Rizzo G, Copetti M, Arcuti S, et al. Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis[J]. Neurology, 2016, 86(6):566-576. doi: 10.1212/WNL.0000000000002350 URL
[4]	Salat D, Noyce AJ, Schrag A, et al. Challenges of modifying disease progression in prediagnostic Parkinson's disease[J]. Lancet Neurol, 2016, 15(6):637-648. doi: 10.1016/S1474-4422(16)00060-0 URL
[5]	Kieburtz K. Treating neurodegenerative disease before illness: a challenge for the 21st century[J]. Lancet Neurol, 2016, 15(6):540-541. doi: 10.1016/S1474-4422(16)30001-1 pmid: 27013350
[6]	Ranzenberger LR, Snyder T. Diffusion tensor imaging[M]. [Updated 2020 May 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2020.
[7]	Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease[J]. Neurology, 2009, 72(16):1378-1384. doi: 10.1212/01.wnl.0000340982.01727.6e pmid: 19129507
[8]	Cochrane CJ, Ebmeier KP. Diffusion tensor imaging in parkinsonian syndromes: A systematic review and meta-analysis[J]. Neurology, 2013, 80(9):857-864. doi: 10.1212/WNL.0b013e318284070c pmid: 23439701
[9]	Deng XY, Wang L, Yang TT, et al. A meta-analysis of diffusion tensor imaging of substantia nigra in patients with Parkinson's disease[J]. Sci Rep, 2018, 8(1):2941. doi: 10.1038/s41598-018-20076-y URL
[10]	Hirata FCC, Sato J R, Vieira G, et al. Substantia nigra fractional anisotropy is not a diagnostic biomarker of Parkinson's disease: A diagnostic performance study and meta-analysis[J]. Eur Radiol, 2017, 27(6):2640-2648. doi: 10.1007/s00330-016-4611-0 URL
[11]	Skorpil M, Söderlund V, Sundin A, et al. MRI diffusion in parkinson's disease: Using the technique's inherent directional information to study the olfactory bulb and substantia nigra[J]. J Parkinsons Dis, 2012, 2(2):171-180.
[12]	Langley J, Huddleston DE, Merritt M, et al. Diffusion tensor imaging of the substantia nigra in Parkinson's disease revisited[J]. Hum Brain Mapp, 2016, 37(7):2547-2556. doi: 10.1002/hbm.23192 pmid: 27029026
[13]	Du G, Lewis MM, Sen S, et al. Imaging nigral pathology and clinical progression in Parkinson's disease[J]. Mov Disord, 2012, 27(13):1636-1643. doi: 10.1002/mds.25182 URL
[14]	Fearnley JM, Lees A J. Ageing and Parkinson's disease: Substantia nigra regional selectivity[J]. Brain, 1991, 114(Pt 5):2283-2301. doi: 10.1093/brain/114.5.2283 URL
[15]	Rolheiser TM, Fulton HG, Good K P, et al. Diffusion tensor imaging and olfactory identification testing in early-stage Parkinson's disease[J]. J Neurol, 2011, 258(7):1254-1260. doi: 10.1007/s00415-011-5915-2 pmid: 21287185
[16]	Joshi N, Rolheiser TM, Fisk JD, et al. Lateralized microstructural changes in early-stage Parkinson's disease in anterior olfactory structures, but not in substantia nigra[J]. J Neurol, 2017, 264(7):1497-1505. doi: 10.1007/s00415-017-8555-3 pmid: 28653210
[17]	Manova ES, Habib CA, Boikov AS, et al. Characterizing the mesencephalon using susceptibility-weighted imaging[J]. AJNR Am J Neuroradiol, 2009, 30(3):569-574. doi: 10.3174/ajnr.A1401 URL
[18]	Wang Z, Luo XG, Gao C. Utility of susceptibility-weighted imaging in Parkinson's disease and atypical Parkinsonian disorders[J]. Transl Neurodegener, 2016, 5:17. doi: 10.1186/s40035-016-0064-2 URL
[19]	郭方亮, 李涛. 帕金森病患者黑质的磁共振成像研究进展[J]. 卒中与神经疾病, 2017, 24(1):65-68.
[20]	Rossi M, Ruottinen H, Soimakallio S, et al. Clinical MRI for iron detection in Parkinson's disease[J]. Clin Imaging, 2013, 37(4):631-636. doi: 10.1016/j.clinimag.2013.02.001 URL
[21]	Prange S, Metereau E, Thobois S, et al. Structural imaging in Parkinson's disease: New developments[J]. Curr Neurol Neurosci Rep, 2019, 19(8):50. doi: 10.1007/s11910-019-0964-5 URL
[22]	Schwarz ST, Afzal M, Morgan PS, et al. The ‘SwallowTail ’ appearance of the healthy nigrosome-A new accurate test of Parkinson's disease: A case-control and retrospective cross-sectional MRI study at 3T[J]. PLoS One, 2014, 9(4:e9814.[eCollection 2014]
[23]	Noh Y, Sung YH, Lee J, et al. Nigrosome 1 detection at 3T MRI for the diagnosis of early-stage idiopathic parkinson disease: Assessment of diagnostic accuracy and agreement on imaging asymmetry and clinical laterality[J]. AJNR Am J Neuroradiol, 2015, 36(11):2010-2016. doi: 10.3174/ajnr.A4412 URL
[24]	Reiter E, Mueller C, Pinter B, et al. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative Parkinsonism[J]. Mov Disord, 2015, 30(8):1068-1076. doi: 10.1002/mds.26171 URL
[25]	陈琪琪, 陈仪婷, 蒋震, 等. 帕金森病患者黑质小体-1影像特征的磁敏感加权成像评价及临床意义[J]. 中华神经科杂志, 2019, 52(8):620-624.
[26]	Mahlknecht P, Krismer F, Poewe W, et al. Meta-analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease[J]. Mov Disord, 2017, 32(4):619-623. doi: 10.1002/mds.26932 URL
[27]	Hellman NE, Gitlin JD. Geruloplasmin metabolism and function[J]. Ann Rev Nutr, 2002, 22(1):439-458. doi: 10.1146/annurev.nutr.22.012502.114457 URL
[28]	Texel SJ, Xu X, Harris ZL. Ceruloplasmin in neurodegenerative diseases[J]. Biochem Soc Trans, 2008, 36(6):1277-1281. doi: 10.1042/BST0361277 URL
[29]	Wang B, Wang X. Does ceruloplasmin defend against neurodegenerative diseases?[J]. Curr Neuropharmacol, 2019, 17(6):539-549. doi: 10.2174/1570159X16666180508113025 pmid: 29737252
[30]	Jin L, Wang J, Jin H, et al. Nigral iron deposition occurs across motor phenotypes of Parkinson’s disease[J]. Eur J Neurol, 2012, 19(7):969-976. doi: 10.1111/j.1468-1331.2011.03658.x pmid: 22288465
[31]	Jin L, Wang J, Zhao L, et al. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease[J]. Brain, 2011, 134(Pt-1):50-58. doi: 10.1093/brain/awq319 URL
[32]	Zhao X, Shao Z, Zhang Y, et al. Ceruloplasmin in Parkinson's disease and the nonmotor symptoms[J]. Brain Behav, 2018, 8(6):e995.[Epub 2018 May 7]
[33]	Wang Z, Luo XG, Gao C. Utility of susceptibility-weighted imaging in Parkinson's disease and atypical Parkinsonian disorders[J]. Transl Neurodegener, 2016, 5:17.[eCollection]
[34]	Bae YJ, Kim JM, Kim E, et al. Loss of nigral hyperintensity on 3 Tesla MRI of Parkinsonism: Comparison with 123I-FP-CIT SPECT[J]. Mov Disord, 2016, 31(5):684-692. doi: 10.1002/mds.v31.5 URL
[35]	Wang N, Yang H, Li C, et al. Using ‘swallow-tail’ sign and putaminal hypointensity as biomarkers to distinguish multiple system atrophy from idiopathic Parkinson's disease: A susceptibility-weighted imaging study[J]. Eur Radiol, 2017, 27(8):3174-3180. doi: 10.1007/s00330-017-4743-x pmid: 28105503
[36]	Boelmans K, Holst B, Hackius M, et al. Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy[J]. Mov Disord, 2012, 27(3):421-427. doi: 10.1002/mds.24926 URL
[37]	Du G, Liu T, Lewis MM, et al. Quantitative susceptibility mapping of the midbrain in Parkinson's disease[J]. Mov Disord, 2016, 31(3):317-324. doi: 10.1002/mds.26417 URL
[38]	Cheng Z, Zhang J, He N, et al. Radiomic features of the nigrosome-1 region of the substantia nigra: Using quantitative susceptibility mapping to assist the diagnosis of idiopathic Parkinson's disease[J]. Front Aging Neurosci, 2019, 11:167. [eCollection]
[39]	Xiao B, He N, Wang Q, et al. Quantitative susceptibility mapping based hybrid feature extraction for diagnosis of Parkinson's disease[J]. Neuroimage Clin, 2019, 24:102070.[Epub 2019 Nov 5] doi: 10.1016/j.nicl.2019.102070 URL
[40]	Martin A, Pietracupa S, Piccini P. Neuromelanin in parkinsonian disorders: An update[J]. Int J Neurosci, 2017, 127(12):1116-1123. doi: 10.1080/00207454.2017.1325883 pmid: 28460588
[41]	Zecca L, Bellei C, Costi P, et al. New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals[J]. Proc Natl Acad Sci USA, 2008, 105(45):17567-17572. doi: 10.1073/pnas.0808768105 URL
[42]	Fasano M, Bergamasco B, Lopiano L. Is neuromelanin changed in Parkinson's disease? Investigations by magnetic spectroscopies[J]. J Neural Transm(Vienna), 2006, 113(6):769-774.
[43]	Xing Y, Sapuan A, Dineen RA, et al. Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI[J]. Mov Disord, 2018, 33(11):1792-1799. doi: 10.1002/mds.27502 URL
[44]	Matsuura K, Maeda M, Tabei K, et al. A longitudinal study of neuromelanin-sensitive magnetic resonance imaging in Parkinson's disease[J]. Neurosci Lett, 2016, 633:112-117. doi: S0304-3940(16)30684-X pmid: 27619539
[45]	Schwarz ST, Xing Y, Tomar P, et al. In vivo assessment of brainstem depigmentation in parkinson disease: Potential as a severity marker for multicenter studies[J]. Radiology, 2017, 283(3):789-798. doi: 10.1148/radiol.2016160662 pmid: 27820685
[46]	Schwarz ST, Rittman T, Gontu V, et al. T1-Weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease[J]. Mov Disord, 2011, 26(9):1633-1638. doi: 10.1002/mds.23722 URL
[47]	Castellanos G, Fernández MA, Lorenzo O, et al. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease[J]. Mov Disord, 2015, 30(7):945-952. doi: 10.1002/mds.v30.7 URL
[48]	Chen X, Huddleston DE, Langley J, et al. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach[J]. Magn Reson Imaging, 2014, 32(10):1301-1306. doi: 10.1016/j.mri.2014.07.003 URL
[49]	Wang J, Li Y, Huang Z, et al. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleusinde novo Parkinson's disease and its phenotypes[J]. Euro J Neurol, 2018, 25(7):949-973. doi: 10.1111/ene.13628 URL
[50]	Ehrminger M, Latimier A, Pyatigorskaya N, et al. The coeruleus/ subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder[J]. Brain, 2016, 139(Pt 4):1180-1188. doi: 10.1093/brain/aww006 pmid: 26920675
[51]	Sommerauer M, Fedorova TD, Hansen AK, et al. Evaluation of the noradrenergic system in Parkinson's disease: An 11C-MeNER PET and neuromelanin MRI study[J]. Brain, 2018, 141(2):496-504. doi: 10.1093/brain/awx348 pmid: 29272343
[52]	Duguid JR, De La Paz R, De Groot J. Magnetic resonance imaging of the midbrain in Parkinson's disease[J]. Ann Neurol, 1986, 20(6):744-747. pmid: 3813504
[53]	马欣昕, 苏闻, 李淑华, 等. 帕金森病患者基底节核团体积的磁共振成像研究[J]. 中华神经科杂志, 2018, 51(3):165-170.
[54]	Oikawa H, Sasaki M, Tamakawa Y, et al. The substantia nigra in Parkinson disease: Proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings[J]. AJNR Am J Neuroradiol, 2002, 23(10):1747-1756.
[55]	Pyatigorskaya N, Gallea C, Garcia-Lorenzo D, et al. A review of the use of magnetic resonance imaging in Parkinson's disease[J]. Ther Adv Neurol Disord, 2014, 7(4):206-220. doi: 10.1177/1756285613511507 URL
[56]	Sohmiya M, Tanaka M, Aihara Y, et al. Structural changes in the midbrain with aging and Parkinson’s disease: An MRI study[J]. Neurobiol Aging, 2004, 25(4):449-453. pmid: 15013565
[57]	Geng DY, Li YX, Zee CS. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease[J]. Neurosurgery, 2006, 58(2):256-62; discussion 256-262. doi: 10.1227/01.NEU.0000194845.19462.7B URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 57

Related Articles 8

Recommended Articles

Metrics

Comments

[1]	Li Ping, Xu Manhua, He Lanying, Wang Lifeng, Zhang Pei, Song Lihua. Aripiprazole and olanzapine on senile dementia of the alzheimer type: A control study [J]. Clinical Focus, 2022, 37(8): 699-703.
[2]	. [J]. Clinical Focus, 2015, 30(5): 569-572.
[3]	. [J]. Clinical Focus, 2014, 29(1): 92-96.
[4]	. [J]. CLINICAL FOCUS, 2010, 25(12): 1080-1081.
[5]	SUN Feng;XING Yong-hong;KONG Ping;ZHANG Ben-shu;ZHANG Yun-ting. Study of 1H magnetic resonance spectroscopy in Parkinson disease with dementia [J]. CLINICAL FOCUS, 2010, 25(5): 401-404.
[6]	. [J]. CLINICAL FOCUS, 2009, 24(10): 918-920.
[7]	. [J]. CLINICAL FOCUS, 2005, 20(19): 1100-1101.
[8]	. Change of neuropeptide Y and immunoglobulin G levels in patients with Alzheimer disease at various high altitude areas [J]. CLINICAL FOCUS, 2004, 19(8): 430-432.